Skip to main navigation Skip to search Skip to main content

Impact of the COVID-19 pandemic on inflammatory bowel disease care in Taiwan: A multicenter study

  • Yen Ling Peng
  • , Chung Hsin Chang
  • , Shu Chen Wei
  • , Tien Yu Huang
  • , Wei Chen Tai
  • , Wen Hung Hsu
  • , Deng Chyang Wu
  • , Hsu Heng Yen
  • , Chi Ming Tai
  • , Chen Wang Chang
  • , Wei Chen Lin
  • , Horng Yuan Wang
  • , Chun Chi Lin
  • , Chia Jung Kuo
  • , Cheng Tang Chiu
  • , Ching Pin Lin
  • , Hsi Chang Lee
  • , Jia Feng Wu
  • , Chen Shuan Chung*
  • *Corresponding author for this work
  • Far Eastern Memorial Hospital
  • Taiwan Society of Inflammatory Bowel Disease
  • Veterans General Hospital-Taichung Taiwan
  • National Taiwan University
  • Taiwan Association for the Study of Small Intestinal Diseases (TASSID)
  • Triservice General Hospital Taiwan
  • Chang Gung Memorial Hospital
  • Kaohsiung Medical University
  • Changhua Christian Hospital
  • I-Shou University
  • Mackay Memorial Hospital Taiwan
  • Mackay Medicine, Nursing and Management College Taiwan
  • Veterans General Hospital-Taipei
  • Chung Shan Medical University
  • Taipei City Hospital
  • Fu Jen Catholic University

Research output: Contribution to journalJournal Article peer-review

3 Scopus citations

Abstract

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic had a great impact on healthcare system and patients. This study aimed to evaluate the effect of the COVID-19 pandemic on the perceptions of patients with inflammatory bowel disease (IBD).

METHODS: This prospective multicenter study was conducted between July 2021 and December 2021. Patients with IBD answered a structured questionnaire, and their degree of anxiety was assessed using a visual analogue scale (VAS) before and after reading educational materials.

RESULTS: A total of 225 (47.67%) patients with Crohn's disease, 244 (51.69%) with ulcerative colitis and 3 (0.64%) with indeterminate colitis were enrolled. Common concerns were adverse events from vaccination (20.34%), and higher risks of developing severe COVID-19 (19.28%) and COVID-19 infection (16.31%) than the general population. Medications deemed by the patients to increase the risk of COVID-19 were immunomodulators (16.10%), anti-tumor necrosis factor-α antagonists (9.96%), and corticosteroids (9.32%). Thirty-five (7.42%) patients self-discontinued IBD medication, of whom 12 (34.28%) had worse symptoms. Older age (>50 years) (OR 1.10, 95% CI 1.01-1.19, p = 0.03), IBD-related complications (OR 1.16, 95% CI 1.04-1.28, p = 0.01), education status below senior high school (OR 1.22, 95% CI 1.08-1.37, p = 0.001), and residing in north-central Taiwan (OR 1.21, 95% CI 1.10-1.34, p < 0.001) were associated with more anxiety. None of the enrolled patients contracted COVID-19. The anxiety VAS score (mean ± SD) improved after reading the educational materials (3.84 ± 2.33 vs. 2.81 ± 1.96, p < 0.001).

CONCLUSION: The medical behavior of IBD patients was influenced by the COVID-19 pandemic, and their anxiety could be mitigated after education.

Original languageEnglish
Pages (from-to)1042-1049
Number of pages8
JournalJournal of the Formosan Medical Association
Volume122
Issue number10
DOIs
StatePublished - 10 2023
Externally publishedYes

Bibliographical note

Copyright © 2023 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • COVID-19
  • Inflammatory bowel disease
  • Patient education
  • SARS-CoV-2
  • Inflammatory Bowel Diseases/complications
  • COVID-19/epidemiology
  • Pandemics
  • Prospective Studies
  • Humans
  • Taiwan/epidemiology

Fingerprint

Dive into the research topics of 'Impact of the COVID-19 pandemic on inflammatory bowel disease care in Taiwan: A multicenter study'. Together they form a unique fingerprint.

Cite this